Lintuzumab: Development discontinued

Seattle Genetics discontinued development of lintuzumab after data from a double-blind, international Phase IIb trial in 211 previously untreated AML patients >=60 years old showed that the compound plus low-dose cytarabine missed the primary endpoint of significantly improving OS vs. placebo plus cytarabine. The company said it plans to fulfill its commitments to support an ongoing investigator-sponsored Phase II trial evaluating lintuzumab to treat myelodysplastic syndrome (MDS), but will completely discontinue its development program for lintuzumab to focus on its lead compound brentuximab vedotin ( SGN-35). ...